Treatment Options in Androgen-Independent Prostate Cancer

References

• Eisenberger M A, Blumenstein B A, Crawford E D, et al. Bilateral orchiectomy with or without fiutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036–1042
   PubMed Web of Science ®Google Scholar
• Gittes R. Carcinoma of the prostate. N Engl J Med 1991; 324: 236–245
   PubMed Web of Science ®Google Scholar
• Scher H I, Kelly W K. Fiutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 1993; 11: 1566–1572
   PubMed Web of Science ®Google Scholar
• Small E J, Carroll P R. Prostate specific antigen decline after Caso-dex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408–410
   PubMed Web of Science ®Google Scholar
• Jenster G, van der Korput H A, van Vroonhoven C, et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991; 5: 1396
   PubMed Web of Science ®Google Scholar
• Taplin M, Bubley G, Shuster T, et al. Mutation of the androgen receptor gene in metastatic androgen independent prostate cancer. N Engl J Med 1995; 332: 1393–1398
   PubMed Web of Science ®Google Scholar
• Hobisch A, Culig Z, Radmayr C, et al. Distant metastases form prostate carcinoma express androgen receptor protein. Cancer Res 1995; 55: 3068–72
   PubMed Web of Science ®Google Scholar
• De Vere White R, Meyers F, Chi S G, et al. Human androgen receptor expression following androgen ablation. Eur Urol 1997; 31: 1–6
   PubMed Web of Science ®Google Scholar
• Bubley G, Balk S. Treatment of metastatic prostate cancer: lessons from the androgen receptor. Hematol Oncol Clin North Am 1996; 10: 713–725
   PubMed Web of Science ®Google Scholar
• Chi S G, de Vere White R W, Meyers F J, et al. P53 in prostate cancer: frequently expressed transition mutations. J Natl Cancer Inst 1994; 86: 926–933
   PubMed Web of Science ®Google Scholar
• McDonell T J, Navone N M, Troscoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997; 157: 569–74
   PubMed Web of Science ®Google Scholar
• Porter A, McEwan A, Powe J, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium 89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805–813
   PubMed Web of Science ®Google Scholar
• Johnson D E, Haynie T P. Phosphoras-32 for intractable pain in carcinoma of the prostate. Urology 1997; 9: 137–139
   Google Scholar
• Cheung A, Driedger A A. Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate. Radiology 1980; 134: 209–212
   PubMed Web of Science ®Google Scholar
• Ahonen A, Joensuu H, Hiltunen J, et al. Samarium- 153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38(4 Suppl)123–127
   PubMedGoogle Scholar
• Collins C, Eary J F, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34: 1839–1844
   PubMed Web of Science ®Google Scholar
• Sandeman T F, Budd R S, Martin J J. Samarium-153-labelled EDTMP for bone marrow metastases from cancer of the prostate. Clin Oncol (R Coll Radiol) 1992; 4: 160–164
   PubMedGoogle Scholar
• Robinson R G, Preston D F, Schiefelbein M, et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420–424
   PubMed Web of Science ®Google Scholar
• Maxon H R, Schroder L E, Hertzberg V S, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991; 32: 1877–1881
   PubMed Web of Science ®Google Scholar
• Srivastava S C, Atkins H L, Krishnamurthy G, et al. Treatment of metastatic bone pain with Tin-117m stannic diethyleneamine-pentacetic acid: a phase I/II clinical study. Clin Cancer Res 1998; 4: 61–68
   PubMed Web of Science ®Google Scholar
• Small E, Vogelzang N. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15: 382–388
   PubMed Web of Science ®Google Scholar
• Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminogluthetimide, in treatment of hormone refractory prostate cancer. J Natl Cancer Inst 1994; 86: 222–227
   PubMed Web of Science ®Google Scholar
• Scher H I, Liebertz C, Kelly W K, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928–2938
   PubMed Web of Science ®Google Scholar
• Liebertz C, Kelly W, Theodoulou M, et al. High dose Casodex for prostate cancer: PSA declines in patients with flutamide withdrawal responses. Proc Am Soc Clin Oncol 1996; 15: 262
   Google Scholar
• Dawson N A, Small E J, Winer E P, et al. Megestrol acetate in men with hormone refractory prostate cancer: prostate specific antigen response and antiandrogen withdrawal data: a Cancer and Leukemia Group B study. Proc Am Soc Clin Oncol 1996; 15: 241
   Google Scholar
• Kelly W, Curley T, Leibertz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen independent prostate cancer. J Clin Oncol 1995; 13: 2208–2213
   PubMed Web of Science ®Google Scholar
• Tannock I, Fospodarowicz M, Meakin W, et al. Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590–597
   PubMed Web of Science ®Google Scholar
• Gerber G S, Chodak G W. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory prostate cancer. J Urol 1990; 144: 1177–1179
   PubMed Web of Science ®Google Scholar
• Sinibaldi V, Carducci M, Abeloff M, et al. Experience with casodex in patients with stage D3 prostate cancer. Proc Am Soc Clin Oncol 1997; 16: 313a
   Google Scholar
• Mani S, Vogelzang N. Is off protocol chemotherapy for androgen independent carcinoma of the prostate warranted?. Hematol Oncol Clin North Am 1996; 10: 749–768
   PubMed Web of Science ®Google Scholar
• Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone refractory prostate cancer. Cancer Invest 1995; 13: 296–312
   PubMed Web of Science ®Google Scholar
• Stearns M E, Tew K D. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 1988; 89: 331–342
   PubMed Web of Science ®Google Scholar
• Loening S A, Beckley S, Brady M F, et al. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 1983; 129: 1001–1006
   PubMed Web of Science ®Google Scholar
• Murphy G P, Gibbons R P, Johnson D E, et al. The use of estramustine phosphate and streptosozin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 1977; 118: 288–291
   PubMed Web of Science ®Google Scholar
• Soloway M S, de Kernion J, Gibbons R, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 1981; 125: 664–667
   PubMed Web of Science ®Google Scholar
• Soloway M S, Beckley S, Brady M, et al. A comparison of estramustine phosphate versus cisplatinum alone versus estramustine phosphate plus cisplatinum in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis and lumbosacral area. J Urol 1983; 129: 56–61
   PubMed Web of Science ®Google Scholar
• DeKernion J N, Murphy G P, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostate cancer. Urology 1988; 31: 312–317
   PubMed Web of Science ®Google Scholar
• Murphy G P, Gibbons R P, Johnson D E, et al. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostate cancer patients who have received prior irradiation. J Urol 1979; 121: 763–765
   PubMed Web of Science ®Google Scholar
• Schmidt J D, Scott W W, Gibbons R P, et al. Comparison of procarbazine, imidazole-carbamide, and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 1979; 121: 185–189
   PubMed Web of Science ®Google Scholar
• Raghavan D, Cox K, Pearson B S, et al. Oral cyclophosphamide for the management of hormone refractory prostate cancer. Br J Urol 1993; 72: 625
   PubMedGoogle Scholar
• Von Roemeling R, Fisher H, Horton J. Daily oral cyclophosphamide is effective in hormone refractory prostate cancer a phase I/II study. Proc Am Soc Clin Oncol 1992; 11: 213
   Google Scholar
• Mahjoubi M, Azalo M, Ghosh M, et al. Phase II trial of ifosfamide in the treatment of metastatic hormone refractory patients with prostate cancer. Cancer Invest 1990; 8: 477–479
   PubMed Web of Science ®Google Scholar
• Torti F, Aston D, Lum B, et al. Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1993; 11: 2167
   PubMedGoogle Scholar
• Kantoff P W, Bryant P, Block C, et al. Fourteen day constant infusion of mitoxantrone HCL for hormone refractory carcinoma of the prostate (HRCaP): a pilot dose finding study. Proc Am Soc Clin Oncol 1991; 10: 175
   Google Scholar
• Knopf R, Knopf K, Ganesh L, et al. Pilot study of low dose weekly mitoxantrone as a single agent in widely metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1993; 12: 250
   Google Scholar
• Osborne C K, Drelichman A, Von Hoff D D, et al. Mitoxantrone: modest activity in a phase II trial in advanced prostate cnacer. Cancer Treat Rep 1983; 67: 1133
   PubMedGoogle Scholar
• Roth B J, Yeap B Y, Wilding G, et al. Taxol in advanced, hormone refractory carcinoma of the prostate. Cancer 1993; 72: 2457–60
   PubMed Web of Science ®Google Scholar
• Hudes G R, Kosierowski R, Greenberg R, et al. Phase II study of topotecan in metastatic hormone refractory prostate cancer. Invest New Drugs 1995; 13: 235–240
   PubMed Web of Science ®Google Scholar
• De Souza P, Cooper M, Inondi A, et al. 9-Aminocaptothecin, a topoisomerase inhibitor with preclinical axtivity against prostate cancer. Proc Am Assoc Cancer Res 1996; 37: 430
   Google Scholar
• Morant R, Ackerman D, Trinkler F, et al. Gemcitabine in hormone refractory metastatic prostatic carcinoma—a phase II study of the SAKK. Proc Am Soc Clin Oncol 1997; 16: 311a
   Google Scholar
• Pienta K J, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005–2012
   PubMed Web of Science ®Google Scholar
• Hudes G R, Greenberg R, Krigel R L, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 1992; 10: 1754–1761
   PubMed Web of Science ®Google Scholar
• Hudes G R, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156–3163
   PubMed Web of Science ®Google Scholar
• Petrylak D P, Shelton G, Judge T, et al. Phase I trial of docetaxel (D) + estramustine (E) in androgen-insensitive prostate cancer (AIP). Proc Am Soc Clin Oncol 1997; 16: 310a
   Google Scholar
• Siu L L, Moore M. Is there a role for chemotherapy in hormone refractory prostate cancer?. Adv Oncol 1996; 12: 22–29
   Google Scholar
• Small E J, Srinivas S, Madhavan S, et al. Use of doxorubicin (D) and dose escalated cyclophosphamide (C) with granulocyte colony stimulating factor (gCSF) in the treatment of hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1995; 13: 243
   Google Scholar
• Walther P J, Keane T E, Walker A N, et al. Treatment of hormone refractory prostate carcinoma with cisplatin and continuous infusion 5FU. Proc Am Soc Clin Oncol 1990; 9: 308
   Google Scholar
• Kantoff P W, Conaway M, Winer E, et al. Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: preliminary results from a prospective randomized Cancer and Leukemia Group B study (9182) comparing chemotherapy to best supportive care. Proc Am Soc Clin Oncol 1996; 15: 2013
   Google Scholar
• Tannock I F, Osoba D, Stockier M, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14: 1756–1764
   PubMed Web of Science ®Google Scholar
• LaRocca R V, Stein C A, Danesi R, Myers C E. Suramin, a novel antitumor compound. J Steroid Biochem Mol Biol 1990; 37: 893–898
   PubMed Web of Science ®Google Scholar
• Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer. J Clin Oncol 1992; 10: 881–889
   PubMed Web of Science ®Google Scholar
• Dawson D A, Figg W D, Brawley O W, et al. Phase II study of suramin plus animogluthetimide in two cohorts of patients with androgen independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res 1998; 4: 37–44
   PubMed Web of Science ®Google Scholar
• Eisenberger M A, Reyno L M, Jodrell D I, et al. Suramin, an active drug for prostate cancer: interim observations in a Phase I trial. J Natl Cancer Inst 1993; 85: 611–621
   PubMed Web of Science ®Google Scholar
• Reyno L M, Egorin M J, Eisenberger M A, et al. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 1995; 13: 2187–2195
   PubMed Web of Science ®Google Scholar
• Kelly W K, Curley T, Leibertz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen independent prostate cancer. J Clin Oncol 1995; 13: 2208–2213
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Vokes E E, Vogelzang N, et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995; 13: 2196–2207
   PubMed Web of Science ®Google Scholar
• Eisenberger M A, Sinibaldi V J, Reyno L M, et al. Phase I and clinical evaluation of pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995; 13: 2174–2186
   PubMed Web of Science ®Google Scholar
• Bowden C J, Gigg W D, Dawson N A, et al. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chermother Pharmacol 1996; 39: 1–8
   PubMed Web of Science ®Google Scholar
• Dawson N A, Cooper M R, Figg W D, et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and fiutamide withdrawal as potentially confounding variables. Cancer 1995; 76: 453–462
   PubMed Web of Science ®Google Scholar
• Solvin S, Larson S, Divgi C, et al. Monoclonal antibody (MoAb) 1131-CC49 and interferon gamma (INF-G): efficacy and therapeutic utility of a phase II trial in hormone insensitive prostate cancer (HIPC). Proc Am Soc Clin Oncol 1996; 15: 444
   Google Scholar
• Roth B J. New therapeutic agents for hormone-refractory prostate cancer. Semin Oncol 1996; 23(6)49–55, Suppl 14
   PubMed Web of Science ®Google Scholar
• O'Connor P M, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285–4300
   PubMed Web of Science ®Google Scholar